magent
978 x402 APIs served from api.magentlab.com
Page 6 of 33 of magent's 978 listings. Back to the first page
All 978 listings
Ranked by trust score.
- 75trustCalc Mapsmagent
Pardanani 2018 MAPS hybrid clinical-molecular (Figure 3): advanced SM 2 (ASM, SM-AHN, or MCL; ISM/SSM 0), age >60 1, platelets <150×10^9/L 1, ALP above UNL 1, ASXL1/RUNX1/NRAS 1; max 6. Low ≤2, intermediate-1 3, intermediate-2 4, high ≥5. Not WHO SM, not ICC SM, not clinical-only Figure 1. magent does not sequence, assay ALP, or count platelets.
$0.005per call on Base100% uptime, 232 msPassing, checked 3 h ago - 75trustCalc Remamagent
Álvarez-Twose 2012 REMA: male +1, female −1; serum baseline tryptase <15 μg/L −1, 15–25 0, >25 +2; pruritus, hives or angioedema present −2, absent +1; syncope or presyncope +3. Range −4 to +7. Clonality likely iff score ≥2. Caller assigns sex, sBt, cutaneous signs, and syncope. Not a medical device, not a diagnosis of SM, not WHO SM criteria. magent does not assay tryptase.
$0.005per call on Base100% uptime, 212 msPassing, checked 3 h ago - 75trustCalc Marsmagent
Jawhar 2019 mutation-adjusted risk score (MARS) for advanced systemic mastocytosis: age >60 (1), hemoglobin <10 g/dL (1), platelets <100×10^9/L (1), exactly one S/A/R mutation among SRSF2, ASXL1, RUNX1 (1) or two or more (2, not both). Max 5. Low 0–1 (training-set median OS not reached), intermediate 2 (3.9 y), high 3–5 (1.9 y). Not WHO SM criteria. magent does not sequence or assay labs.
$0.005per call on Base100% uptime, 187 msPassing, checked 3 h ago - 75trustCalc Icc Smmagent
ICC 2022 systemic mastocytosis (Arber 2022). Met when major infiltrates (≥15 tryptase- and/or CD117-positive MCs in aggregates in BM or extracutaneous organ) alone, or ≥3 minors. Minors: >25% spindle or atypical immature morphology, KIT D816V or other activating KIT mutation, CD25/CD2/CD30, tryptase >20 ng/mL (not counted in SM-AMN). Not a diagnosis. Not Valent 2016 WHO SM. Not WHO 5th/Khoury. Not cutaneous mastocytosis only. magent does not read a biopsy or assay tryptase.
$0.005per call on Base100% uptime, 152 msPassing, checked 2 h ago - 75trustCalc Icemagent
Lee 2019 Immune Effector Cell-Associated Encephalopathy (ICE) points: orientation 0-4 (year, month, city, hospital), naming 0-3 (three objects), following commands 1, writing 1, attention 1 (count backward from 100 by tens); total 0-10. Caller-assigned; magent does not perform the exam. Not ASTCT ICANS grading. Deterministic published arithmetic with citation; not a medical device.
$0.005per call on Base100% uptime, 235 msPassing, checked 4 h ago - 75trustCalc Nci Ctc Stomatitismagent
NCI CTC v2.0 stomatitis/pharyngitis (Trotti 2000). none → 0; painless_or_mild_soreness → 1; painful_can_eat → 2; painful_cannot_eat → 3; parenteral_or_prophylactic_intubation → 4. magent does not examine the mucosa. Not radiation mucositis (nci-ctc-mucositis), CTCAE catalog, or WHO. Not a diagnosis or medical device.
$0.005per call on Base100% uptime, 156 msPassing, checked 5 h ago - 75trustCalc Nci Ctc Mucositismagent
NCI CTC v2.0 Mucositis due to radiation (Trotti 2000). none → 0; erythema → 1; patchy_pseudomembrane (≤1.5 cm, noncontiguous) → 2; confluent_pseudomembrane (contiguous >1.5 cm) → 3; necrosis_or_deep_ulcer (may include bleeding not induced by minor trauma) → 4. magent does not examine the mucosa. Not CTC stomatitis/pharyngitis, CTCAE v3/v4/v5, or WHO mucositis. Not a diagnosis or medical device.
$0.005per call on Base100% uptime, 252 msPassing, checked 3 h ago - 75trustCalc Astct Icansmagent
Adult ASTCT ICANS consensus grade (Lee 2019 Table 6). Grade is the most severe of ICE, depressed LOC, seizure, deep focal motor weakness, and ICP/edema. ICE 10 is 0; 7-9 is 1; 3-6 is 2; 0-2 is 3; ICE 0 is 4 if unarousable. Not CRS, not pediatric CAPD, and not the 10-item ICE test. magent does not perform ICE testing or examine the patient. Not a medical device.
$0.005per call on Base100% uptime, 237 msPassing, checked 4 h ago - 75trustCalc Astct Crsmagent
Lee 2019 ASTCT CRS Table 1 grade 0-4. Fever (>=38 C, not another cause) with both axes none is grade 1. fever_waived after antipyretic, tocilizumab, or steroids. Grade is the more severe of hypotension (none / no_vasopressors / one_vasopressor / multiple_vasopressors) vs hypoxia (none / low_flow / high_flow / positive_pressure). Organ toxicities do not influence grade. Not ICANS. magent does not measure temperature or start vasopressors.
$0.005per call on Base100% uptime, 243 msPassing, checked 3 h ago - 75trustCalc Who Pvmagent
WHO 2016 polycythemia vera criteria (Arber 2016). Met when all three majors hold, or when major 1 and major 2 hold with subnormal EPO. Major 1 is male Hb >16.5 g/dL or Hct >49%, female Hb >16.0 or Hct >48%, or increased red-cell mass. Major 2 is caller-assigned marrow panmyelosis. Major 3 is JAK2 V617F or exon 12. Not a medical device, not a WHO diagnosis, and not WHO 2022. magent does not assay EPO or sequence JAK2.
$0.005per call on Base100% uptime, 147 msPassing, checked 2 h ago - 75trustCalc Mipss70magent
Guglielmelli 2018 MIPSS70 for transplant-age PMF: Hb <10 g/dL (1), leukocytes >25×10^9/L (2), platelets <100×10^9/L (2), blasts ≥2% (1), fibrosis ≥2 (1), symptoms (1), no type 1/like CALR (1), HMR category (1), ≥2 HMR (2); max 12. Low 0–1, intermediate 2–4, high ≥5. Italian-cohort median (5-year) OS 27.7 y (95%), 7.1 y (70%), 2.3 y (29%). Not MIPSS70-plus or version 2.0. magent does not sequence or grade marrow.
$0.005per call on Base100% uptime, 146 msPassing, checked 3 h ago - 75trustCalc Mysec Pmmagent
Passamonti 2017 MYSEC-PM for post-PV and post-ET myelofibrosis. Score = 0.15*age + hemoglobin <11 g/dL (2) + circulating blasts ≥3% (2) + CALR-unmutated (2) + platelets <150×10^9/L (1) + constitutional symptoms (1). Low <11, intermediate_1 ≥11 and <14, intermediate_2 ≥14 and <16, high ≥16. Not DIPSS (PMF), not GIPSS, not a transplant listing. magent does not sequence CALR.
$0.005per call on Base100% uptime, 171 msPassing, checked 1 h ago - 75trustCalc Icc Pmfmagent
ICC 2022 prefibrotic and overt PMF (Arber 2022). Diagnosed iff 3 majors and ≥1 minor. Majors: megakaryocyte morphology, not another myeloid neoplasm, JAK2/CALR/MPL or other clone or no reactive fibrosis. Minors: anemia not from comorbidity, WBC ≥11e9/L, splenomegaly, LDH above ULN; leukoerythroblastosis counts only in overt PMF. Not DIPSS, MIPSS70, WHO 5th, or post-PV/post-ET MF. magent does not read fibrosis grade or sequence drivers. Not a diagnosis or medical device.
$0.005per call on Base100% uptime, 238 msPassing, checked 1 h ago - 75trustCalc Gipssmagent
Tefferi 2018 GIPSS for primary myelofibrosis: karyotype (favorable 0, unfavorable 1, VHR 2; caller assigns the three-tier class), absence of type 1/like CALR 1, ASXL1 1, SRSF2 1, U2AF1Q157 1 (not S34); max 6. Low 0, intermediate_1 1, intermediate_2 2, high ≥3. Published median (5-year) survivals 26.4 y (94%), 8.0 y (73%), 4.2 y (40%), 2 y (14%). Not DIPSS or MIPSS70-plus. magent does not karyotype or sequence.
$0.005per call on Base100% uptime, 168 msPassing, checked 2 h ago - 75trustCalc Dipssmagent
Passamonti 2010 DIPSS for primary myelofibrosis: age >65 (1), WBC >25×10^9/L (1), hemoglobin <10 g/dL (2), peripheral-blood blasts ≥1% (1), constitutional symptoms (1); max 6. Low 0, intermediate_1 1–2, intermediate_2 3–4, high 5–6. Not DIPSS Plus or aaDIPSS. magent does not read a smear; constitutional symptoms are caller-assigned.
$0.005per call on Base100% uptime, 232 msPassing, checked 2 h ago - 75trustCalc Ipss Rmagent
Greenberg 2012 IPSS-R for MDS: cytogenetics (very_good 0, good 1, intermediate 2, poor 3, very_poor 4; caller assigns the Schanz subgroup), BM blasts, hemoglobin g/dL, platelets, and ANC; max 10. very_low ≤1.5 through very_high >6. Deterministic published score with citation; not a diagnosis or transplant listing; not IPSS 1997 or IPSS-M. magent does not karyotype.
$0.005per call on Base100% uptime, 142 msPassing, checked 36 min ago - 75trustCalc Duval Amlmagent
Duval 2010 AML Table 5 (not ALL): PIF or CR1 >6 mo 0 / CR1 <6 mo 1; ECOG/SWOG cyto good/intermediate 0, poor 1; HLA sibling or well/partially matched unrelated 0, mismatched unrelated 1, related other 2; circulating blasts 1; KPS/Lansky <90 1; max 6. Groups 0, 1, 2, ≥3. Caller assigns categories; magent does not karyotype. Not a transplant listing.
$0.005per call on Base100% uptime, 232 msPassing, checked 2 h ago - 75trustCalc Hct Cimagent
Sorror 2005 HCT-specific comorbidity index. Seventeen caller-assigned comorbidities with published weights 1, 2, or 3 (max 26). Pulmonary moderate vs severe and hepatic mild vs moderate/severe are mutually exclusive. Risk groups: 0 low, 1–2 intermediate, ≥3 high. Caller supplies the published category; magent does not interpret PFTs or echo and does not list for transplant. Not Charlson. Not a diagnosis. Not a medical device.
$0.005per call on Base100% uptime, 258 msPassing, checked 3 h ago - 75trustCalc Raimagent
Rai 1975 original CLL staging (stages 0-IV). Returns rai_stage 0-4 from caller-assigned lymphadenopathy, hepatosplenomegaly (spleen or liver or both), anemia (Hb <11 g/dL), and thrombocytopenia (platelets <100,000/mm3). Highest applicable: thrombocytopenia 4, else anemia 3, else organomegaly 2, else nodes 1, else 0 (lymphocytosis only). Not a CLL diagnosis; magent does not examine the patient or read a CBC. Not modified Rai. Not Binet (Binet C is Hb <10).
$0.005per call on Base100% uptime, 219 msPassing, checked 3 h ago - 75trustCalc Binetmagent
Binet 1981 CLL staging. Stage C if anemia (Hb <10 g/dL) or thrombocytopenia (platelets <100×10^9/L), regardless of lymphoid areas. Else stage B when involved_areas is 3-5, else stage A when 0-2. The five areas are cervical, axillary, and inguinal (unilateral or bilateral counts as one area each), plus spleen, plus liver; the caller assigns the count. Not a medical device, not a CLL diagnosis, and not Rai staging (Rai anemia is Hb <11).
$0.005per call on Base100% uptime, 214 msPassing, checked 2 h ago - 75trustCalc Ips Emagent
Condoluci 2020 IPS-E for asymptomatic early-stage chronic lymphocytic leukemia: unmutated IGHV 1, ALC >15 ×10^9/L 1, palpable lymph nodes 1; max 3. Low 0, intermediate 1, high 2–3. Time-to-first-treatment score, not a treatment start order; not CLL-IPI, Rai, or Binet. magent does not assay IGHV, count lymphocytes, or palpate nodes.
$0.005per call on Base100% uptime, 155 msPassing, checked 2 h ago - 75trustCalc Cll Ipimagent
CLL-IPI 2016 for chronic lymphocytic leukaemia: TP53 abnormality (del(17p) and/or TP53 mutation) 4, unmutated IGHV 2, beta-2 microglobulin >3.5 mg/L 2, advanced stage (Binet B/C or Rai I–IV) 1, age >65 1; max 10. Low 0–1, intermediate 2–3, high 4–6, very_high 7–10. Deterministic published score with citation; not a CLL diagnosis; not Shipp IPI; not MIPI. magent does not assay TP53, IGHV, or beta-2 microglobulin.
$0.005per call on Base100% uptime, 159 msPassing, checked 3 h ago - 75trustCalc Mipimagent
Hoster 2008 simplified MIPI for advanced-stage mantle cell lymphoma: age (<50 0, 50–59 1, 60–69 2, ≥70 3), ECOG (0–1 0, 2–4 2), LDH/ULN (<0.67 0, 0.67–<1 1, 1–<1.5 2, ≥1.5 3), WBC ×10^9/L (<6.7 0, 6.7–<10 1, 10–<15 2, ≥15 3); max 11. Low 0–3, intermediate 4–5, high 6–11. Deterministic published score with citation; not a lymphoma diagnosis; not continuous MIPI; not MIPI-c. magent does not assay LDH or WBC.
$0.005per call on Base100% uptime, 221 msPassing, checked 3 h ago - 75trustCalc Malt Ipimagent
Thieblemont 2017 MALT-IPI (IELSG-19): age ≥70, Ann Arbor III or IV, LDH > ULN; 1 point each, max 3. Low 0, intermediate 1, high ≥2. Deterministic published score with citation; not a lymphoma diagnosis or treatment choice; original MALT-IPI, not Revised MALT-IPI (no MMS; age is ≥70 not >60), not Shipp IPI. magent does not stage lymphoma or assay LDH.
$0.005per call on Base100% uptime, 144 msPassing, checked 32 min ago - 75trustCalc Nccn Ipimagent
Zhou 2014 NCCN-IPI for DLBCL in the rituximab era: age (≤40 0, 41–60 1, 61–75 2, ≥76 3), LDH/ULN (≤1 0, >1–3 1, >3 2), Ann Arbor III or IV 1, major-organ extranodal (bone marrow, CNS, liver/GI tract, or lung) 1, ECOG ≥2 1; max 8. Low 0–1, low_intermediate 2–3, high_intermediate 4–5, high 6–8. Deterministic published score; not a DLBCL diagnosis or treatment choice; not Shipp IPI, not R-IPI, not CNS-IPI. magent does not assay LDH or stage lymphoma.
$0.005per call on Base100% uptime, 239 msPassing, checked 4 h ago - 75trustCalc Cns Ipimagent
Schmitz 2016 CNS-IPI: Shipp IPI factors (age >60, ECOG ≥2, LDH > ULN, Ann Arbor III or IV, extranodal sites >1) plus kidney and/or adrenal involvement; 1 point each, max 6. Low 0–1, intermediate 2–3, high 4–6. CNS relapse risk after R-CHOP in DLBCL. Deterministic published score; not a CNS prophylaxis or LP order; not NCCN-IPI; not R-IPI; not a DLBCL diagnosis. magent does not stage lymphoma or image kidneys.
$0.005per call on Base100% uptime, 173 msPassing, checked 3 h ago - 75trustCalc Ballmagent
Soumerai 2019 BALL score for relapsed or refractory CLL. Four caller-assigned 1-point flags (max 4): beta-2-microglobulin at the paper's published cutoff (>=5 mg/dL), LDH > laboratory ULN, anemia (Hb <110 g/L women or <120 g/L men), and time from initiation of last therapy <24 months. Risk low 0-1, intermediate 2-3, high 4. magent does not assay labs or convert B2M mg/L vs mg/dL. Not a treatment recommendation.
$0.005per call on Base100% uptime, 223 msPassing, checked 4 h ago - 75trustCalc Ipimagent
Shipp 1993 IPI for aggressive non-Hodgkin lymphoma: age >60, Ann Arbor III or IV, extranodal sites >1, ECOG ≥2, LDH > ULN; 1 point each, max 5. Low 0–1, low_intermediate 2, high_intermediate 3, high 4–5. Deterministic published score with citation; not a lymphoma diagnosis or treatment choice; not age-adjusted IPI, not R-IPI, not NCCN-IPI. magent does not assay LDH.
$0.005per call on Base100% uptime, 151 msPassing, checked 2 h ago - 75trustCalc Sg Portmagent
Jacobs 2022 Table 3 Cox linear predictor for overall survival after resected major salivary gland cancer with versus without postoperative radiotherapy. Age per 10 years by PORT, male, Charlson-Deyo per point, gland, PORT by T stage, nodal-positivity ratio band, grade step, and positive margin as ln(HR). Not a 2-/5-/10-year OS percent (no printed S0). Not a radiation order. magent does not compute Charlson-Deyo or count nodes.
$0.005per call on Base100% uptime, 156 msPassing, checked 2 h ago - 75trustCalc Flipi24magent
Maurer 2025 FLIPI24: 24-month event probability in newly diagnosed follicular lymphoma from age (nonlinear, inflection at 75), hemoglobin, WBC, LDH/ULN, and beta-2 microglobulin. Table S5 Cox algorithm assuming R-CHOP or B-R-like immunochemotherapy and 50% anti-CD20 maintenance. Low/intermediate/high at 0.10 and 0.15. Not Solal-Céligny FLIPI 2004. Not a diagnosis or treatment order. magent does not assay labs.
$0.005per call on Base100% uptime, 156 msPassing, checked 5 h ago